serolog
molecular
phylogenet
analys
recent
import
case
middl
east
respiratori
syndrom
coronaviru
merscov
greec
report
although
merscov
remain
detect
respiratori
tract
secret
patient
fourth
week
ill
viraemia
last
detect
day
initi
tripl
combin
therapi
pegyl
interferon
ribavirin
lopinavirritonavir
administ
day
ill
phylogenet
analysi
viru
show
close
similar
human
merscov
recent
jeddah
outbreak
saudi
arabia
immunoglobulin
g
igg
titr
peak
week
onset
ill
whilst
igm
level
remain
constantli
elev
followup
period
second
fifth
week
ill
serolog
test
confirm
viru
neutralis
assay
detect
addit
case
close
contact
patient
upsurg
middl
east
respiratori
syndrom
coronaviru
merscov
infect
recent
describ
countri
arabian
peninsula
result
export
case
countri
european
union
case
merscov
infect
associ
high
case
fatal
rate
sinc
avail
treatment
scarciti
data
specif
therapeut
intervent
diseas
publish
report
propos
use
known
antivir
base
extrapol
data
sever
acut
respiratori
syndrom
sar
epidem
also
associ
circul
novel
coronaviru
ii
vitro
data
iii
anim
experiment
infect
therapi
data
iv
limit
clinic
data
actual
merscov
infect
howev
clearcut
recommend
therapeut
regimen
exist
evid
grade
intervent
gener
low
except
use
convalesc
serum
base
biolog
effect
given
highest
grade
moreov
littl
known
viral
kinet
merscovassoci
infect
especi
specif
antivir
therapeut
intervent
attempt
case
merscov
recent
describ
greec
travel
extens
contact
healthcar
environ
jeddah
saudi
arabia
describ
molecular
serolog
phylogenet
analys
case
well
evid
second
case
close
contact
first
patient
furthermor
provid
evid
kinet
pattern
viral
excret
biolog
specimen
obtain
first
greek
case
patient
tripl
antivir
regimen
preliminari
report
first
import
laboratoryconfirm
merscov
case
greec
describ
elsewher
full
descript
cours
ill
treatment
regimen
http
relat
kinet
viru
shed
immun
respons
prepar
review
patient
record
cours
outbreak
investig
patient
contact
includ
patient
wife
provid
oropharyng
sampl
pcr
test
week
contact
posit
case
addit
contact
includ
serolog
examin
group
submit
person
clinic
monitor
fever
upper
respiratori
infect
symptom
advis
call
hellen
centr
diseas
control
prevent
cdc
command
centr
immedi
instanc
addit
offer
chanc
provid
serum
sampl
voluntari
basi
specif
antim
antibodi
test
baselin
time
oropharyng
pcr
test
week
exposur
patient
stay
intens
care
unit
icu
sampl
oropharynx
trachea
urin
faec
test
diagnost
evalu
monitor
viral
shed
realtim
revers
transcript
pcr
rtpcr
method
base
amplif
upstream
envelop
gene
upe
nucleocapsid
n
gene
open
read
frame
orf
viru
use
detect
merscov
accord
previous
describ
methodolog
immunoglobulin
g
igg
igm
antibodi
titr
serum
sampl
determin
use
antimerscov
indirect
immunofluoresc
assay
euroimmun
ag
germani
confirm
serolog
find
perform
viru
neutralis
assay
describ
previous
sampl
patient
upper
respiratori
tract
underw
convent
molecular
test
presenc
respiratori
pathogen
thu
cultur
appli
bacteri
test
whilst
realtim
rtpcr
perform
sever
respiratori
virus
includ
influenza
b
virus
respiratori
syncyti
viru
rsv
parainfluenza
adenoviru
enteroviru
bocaviru
human
metapneumoviru
hmpv
mw
rgene
franc
specif
urin
antigen
test
urin
sampl
utilis
legionella
pneumophila
streptococcu
pneumonia
binaxnow
aler
orlando
fl
stool
cultur
perform
due
histori
possibl
typhoid
fever
diagnos
treat
physician
saudi
arabia
nucleotid
sequenc
concaten
sequenc
repres
merscov
analys
phylogenet
tree
construct
phyml
method
describ
previous
patient
greek
origin
perman
resid
jeddah
present
tertiari
care
centr
hour
arriv
athen
greec
april
chief
complaint
includ
fever
sinc
april
diarrhoea
sinc
april
like
sourc
exposur
hospit
environ
jeddah
patient
known
comorbid
time
initi
evalu
fever
c
note
togeth
low
oxygen
satur
although
patient
exhibit
minim
respiratori
symptom
chest
radiograph
depict
bilater
lung
infiltr
consist
viral
pneumonia
patient
immedi
place
isol
suspicion
merscov
infect
antimicrobi
regimen
target
communityacquir
pneumonia
initi
april
merscov
infect
confirm
mean
viral
rna
detect
pharyng
swab
depart
microbiolog
univers
athen
medic
school
athen
greec
laboratori
confirm
merscov
patient
transfer
specialis
respiratori
diseas
unit
sotiria
chest
diseas
hospit
athen
treat
neg
pressur
regular
room
isol
april
due
deterior
respiratori
function
develop
acut
respiratori
diseas
syndrom
ard
intub
ventil
transfer
neg
pressur
room
icu
hospit
empir
antivir
regimen
initi
day
ill
consist
oral
po
lopinavirritonavir
mg
twice
daili
pegyl
interferon
g
subcutan
per
week
day
ribavirin
mg
po
load
dose
follow
mg
po
everi
h
day
base
avail
evid
fig
patient
remain
intub
exhibit
hypoxia
occasion
hypercapnia
breath
inspir
oxygen
rang
remain
febril
plateau
temperatur
c
maximum
valu
c
day
ill
fever
start
subsid
c
day
acut
kidney
injuri
diagnos
day
ill
rapidli
progress
nonoligur
renal
failur
revert
rifl
injuri
level
ie
twofold
increas
serum
creatinin
glomerular
filtrat
rate
decreas
urin
output
mlkgh
h
day
patient
diarrhoea
resolv
gradual
start
day
develop
constip
thereaft
normalis
bowel
movement
gastrointestin
function
day
owe
develop
jaundic
hyperbilirubinaemia
attribut
ribavirin
drug
discontinu
day
cours
hospitalis
patient
diagnos
adenocarcinoma
colon
eventu
die
septic
shock
month
day
initi
diagnosi
cultur
antigen
detect
neg
l
pneumophila
pneumonia
virolog
test
neg
presenc
respiratori
viru
relev
enter
pathogen
identifi
caus
patient
diarrhoea
rna
detect
sever
consecut
patient
sampl
differ
site
includ
faecal
materi
serum
fig
shed
merscov
respiratori
secret
patient
note
fourth
week
ill
wherea
viraemia
last
detect
day
onset
ill
day
initi
tripl
combin
antivir
regimen
consecut
urin
test
reveal
presenc
merscov
rna
fig
serolog
test
show
peak
igg
titr
third
week
ill
whilst
fourth
fifth
week
igg
titr
substanti
declin
igm
titr
persist
elev
whole
survey
period
day
day
ill
fig
viral
neutralis
assay
perform
erasmu
medic
center
rotterdam
netherland
confirm
immunofluoresc
test
result
initi
followup
serolog
test
perform
serum
sampl
patient
contact
seroconvers
reveal
one
develop
igg
titr
igm
titr
day
make
contact
patient
man
past
medic
histori
coronari
arteri
heart
diseas
diabet
presenc
specif
merscov
antibodi
confirm
viru
neutralis
assay
without
symptom
system
nasopharyng
pcr
test
perform
time
sinc
outsid
incub
period
day
well
sinc
time
symptomat
contact
famili
member
four
person
initi
patient
wife
brief
episod
fever
may
oropharyng
pcr
test
neg
merscov
contact
remain
seroneg
repeat
test
partial
genom
sequenc
reveal
close
phylogenet
relationship
clinic
merscov
strain
associ
sever
respiratori
infect
patient
jeddah
fig
report
characteris
serolog
virolog
paramet
first
merscov
case
greec
rise
titr
igg
demonstr
sequenti
serum
sampl
peak
titr
approxim
week
cours
diseas
accord
serolog
test
guidanc
world
health
organ
recommend
baselin
test
initi
contact
affect
case
repeat
serolog
test
day
hand
igm
titr
patient
remain
constantli
elev
threshold
detect
albeit
lower
level
igg
antibodi
prolong
period
month
followup
thu
isol
use
igm
test
without
concomit
igg
determin
appear
suffici
reveal
recent
infect
note
howev
absenc
detail
studi
use
serolog
test
merscov
detect
human
need
evalu
prolong
shed
viru
note
respiratori
tract
patient
find
consist
data
regard
sar
coronaviru
report
deal
patient
affect
sar
prolong
shed
viru
note
stool
day
respiratori
specimen
day
data
regard
length
merscov
excret
differ
bodi
site
scarc
excret
viru
probabl
depend
amplitud
replic
differ
bodi
site
underli
immun
statu
comorbid
appropri
antivir
therapi
nondetect
viral
rna
serum
day
initi
antivir
treatment
could
explain
either
viral
clearanc
otherwis
immunocompet
person
effect
institut
antivir
regimen
literatur
appropri
antivir
intervent
merscov
limit
current
evidencebas
therapi
exist
regimen
chosen
base
best
avail
literatur
well
evid
anim
patient
data
describ
elsewher
role
interferon
therapi
merscov
infect
need
elucid
attenu
respons
describ
result
merscov
infect
extens
use
interferonbas
regimen
alon
combin
ribavirin
describ
sar
howev
interferon
appear
better
antivir
effect
merscov
compar
sarscov
vitro
experi
vitro
appear
exhibit
best
antimerscov
effect
interferon
activ
enhanc
addit
ribavirin
vitro
experi
furthermor
combin
shown
promis
clinic
radiolog
effect
rhesu
macaqu
experiment
infect
merscov
thu
clinic
team
elect
use
combin
despit
fact
prestigi
public
health
agenc
rank
ribavirin
use
support
highqual
evid
recent
updat
publish
public
health
agenc
use
interferon
lopinavir
rank
recommend
benefit
like
exceed
risk
wherea
combin
interferon
ribavirin
rank
data
inadequ
assess
frequent
side
effect
ribavirin
limit
use
combin
regimen
actual
merscovinfect
patient
experi
current
patient
liver
toxic
although
definit
associ
mainli
attribut
medic
renal
function
deterior
patient
describ
consid
multifactori
probabl
also
complic
viru
infect
possibl
drug
toxic
might
contribut
renal
dysfunct
could
exclud
howev
drug
level
measur
sinc
patient
continu
renal
replac
therapi
time
drug
level
would
unreli
actual
clinic
human
set
combin
ribavirin
interferon
tri
success
outcom
report
among
merscovinfect
recipi
nevertheless
group
studi
consist
sever
ill
patient
receiv
combin
quit
late
cours
diseas
lastli
ad
proteas
inhibitor
lopinavirritonavir
base
experi
accumul
sar
epidem
addit
agent
ribavirin
improv
outcom
infect
expand
knowledg
regard
viral
kinet
pattern
shed
especi
associ
specif
therapeut
intervent
import
implic
infect
control
healthcar
environ
especi
relat
potenti
transmiss
patient
healthcar
worker
phylogenet
analysi
greek
merscov
strain
show
close
similar
circul
patient
viral
strain
recent
jeddah
outbreak
well
strain
isol
dromedari
camel
qatar
accord
previou
genet
studi
shown
ident
viral
strain
infect
human
dromedari
camel
gener
hypothesi
dromedari
camel
among
reservoir
viru
natur
also
presenc
merscovspecif
antibodi
camel
across
wide
geograph
area
africa
arabian
peninsula
signifi
possibl
zoonot
transmiss
camel
human
potenti
transmiss
across
differ
individu
strain
explor
patient
like
sourc
exposur
hospit
environ
endem
area
wife
hospitalis
local
hospit
jeddah
appear
healthcareassoci
outbreak
play
pivot
role
evolut
merscov
epidem
recent
upsurg
conclus
describ
genet
stabil
merscov
strain
recent
jeddah
outbreak
although
reassur
find
limit
level
awar
regard
increas
number
case
arabian
peninsula
report
recent
potenti
evolut
effici
transmiss
viru
committe
recent
conclud
condit
public
health
emerg
intern
concern
yet
met
nevertheless
import
gap
current
knowledg
merscov
exist
investig
clarifi
natur
reservoir
mode
transmiss
necessari
persist
viru
shed
patient
secret
effect
immun
statu
antivir
therapi
togeth
implement
appropri
infect
control
measur
paramount
import
limit
spread
potenti
lethal
viru
fund
work
fund
grant
netherland
organis
scientif
research
nwo
compet
interest
none
declar
ethic
approv
requir
